ImmuneOnco appointed Mr. Huang Cheng as the vice general manager in charge of clinical medicine department

"I am very honored to join the team of ImmuneOnco, which focuses on original drug research, especially in the innovative drug research with CD47 target as the core, and has its own unique advantages and characteristics. With the rapid develop...

2020-05-26

Recruitment of clinical trials of IMM0306 in the treatment of refractory or recurrent CD20 positive B-cell non Hodgkin's lymphoma

IMM0306 is a recombinant human SIRPα and anti-CD20 antibody fusion protein, which is independently developed by ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. IMM0306 can bind to CD20 on tumor cell membrane and kill tumor cells through ADCP, ADCC and CDC; ......

2020-05-14

The Phase I clinical trial launching meeting of IMM0306 project was held

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company is mainly committed to the development and research of tumor immunotherap......

2020-04-17

Patient in the second dose group of IMM01 project continued to benefit

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company is mainly committed to the development and research of tumor immunotherapy products. The product lin......

2020-04-15

The second dose group clinical trial of IMM01 project was successfully completed

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company is mainly committed to the development and research of tumor immunotherapy products. The product line main...

2020-03-26